Cargando…

Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation

To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ran, Lu, Xuan, Tang, Liang V., Wang, Huafang, Yan, Han, You, Yong, Zhong, Zhaodong, Shi, Wei, Xia, Linghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520486/
https://www.ncbi.nlm.nih.gov/pubmed/36189288
http://dx.doi.org/10.3389/fimmu.2022.993419
_version_ 1784799635283378176
author Zhang, Ran
Lu, Xuan
Tang, Liang V.
Wang, Huafang
Yan, Han
You, Yong
Zhong, Zhaodong
Shi, Wei
Xia, Linghui
author_facet Zhang, Ran
Lu, Xuan
Tang, Liang V.
Wang, Huafang
Yan, Han
You, Yong
Zhong, Zhaodong
Shi, Wei
Xia, Linghui
author_sort Zhang, Ran
collection PubMed
description To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05×10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20×10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up.
format Online
Article
Text
id pubmed-9520486
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95204862022-09-30 Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation Zhang, Ran Lu, Xuan Tang, Liang V. Wang, Huafang Yan, Han You, Yong Zhong, Zhaodong Shi, Wei Xia, Linghui Front Immunol Immunology To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05×10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20×10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520486/ /pubmed/36189288 http://dx.doi.org/10.3389/fimmu.2022.993419 Text en Copyright © 2022 Zhang, Lu, Tang, Wang, Yan, You, Zhong, Shi and Xia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Ran
Lu, Xuan
Tang, Liang V.
Wang, Huafang
Yan, Han
You, Yong
Zhong, Zhaodong
Shi, Wei
Xia, Linghui
Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
title Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
title_full Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
title_fullStr Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
title_full_unstemmed Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
title_short Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation
title_sort influence of graft composition in patients with hematological malignancies undergoing atg-based haploidentical stem cell transplantation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520486/
https://www.ncbi.nlm.nih.gov/pubmed/36189288
http://dx.doi.org/10.3389/fimmu.2022.993419
work_keys_str_mv AT zhangran influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT luxuan influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT tangliangv influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT wanghuafang influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT yanhan influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT youyong influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT zhongzhaodong influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT shiwei influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation
AT xialinghui influenceofgraftcompositioninpatientswithhematologicalmalignanciesundergoingatgbasedhaploidenticalstemcelltransplantation